The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for prostate cancer to include recommendations for Clovis Oncology’s (NASDAQ:CLVS)
Rubraca (rucaparib) for the treatment of BRCA-mutant patients with
mCRPC (metastatic castration-resistant prostate cancer) under
second-line treatment and subsequent therapy as a Category 2A
recommendation inclusive of the following:
Rucaparib is a treatment option for patients with
mCRPC and a pathogenic BRCA1 or BRCA2 mutation (germline and/or somatic)
who have been treated with androgen receptor-directed therapy and a
taxane-based chemotherapy. If the patient is not fit for chemotherapy,
rucaparib can be considered even if taxane-based therapy has not been
given.
https://seekingalpha.com/news/3578243-cancer-treatment-guidelines-add-new-recommendations-for-clovis-rubraca
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.